Apr 29 |
SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL phase 3 study without modifications
|
Apr 29 |
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
|
Apr 19 |
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
|
Mar 28 |
SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24
|
Mar 28 |
SELLAS Life Sciences Group files for $200M mixed shelf
|
Mar 28 |
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 26 |
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
|
Mar 19 |
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
Mar 19 |
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
|
Mar 15 |
SELLAS Life Sciences looks to raise $20M in a direct offering
|